Intec Pharma Ltd. (NASDAQ:NTEC) and Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI), both competing one another are Biotechnology companies. We will contrast their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.
Valuation and Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Intec Pharma Ltd.||N/A||0.00||41.18M||-1.40||0.00|
|Spectrum Pharmaceuticals Inc.||108.50M||10.81||99.35M||-0.60||0.00|
Table 1 shows the gross revenue, earnings per share and valuation for Intec Pharma Ltd. and Spectrum Pharmaceuticals Inc.
Table 2 has Intec Pharma Ltd. and Spectrum Pharmaceuticals Inc.â€™s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Intec Pharma Ltd.||0.00%||0%||0%|
|Spectrum Pharmaceuticals Inc.||-91.57%||-30.6%||-22.1%|
Ratings and Recommendations for Intec Pharma Ltd. and Spectrum Pharmaceuticals Inc. can be find in next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Intec Pharma Ltd.||0||0||0||0.00|
|Spectrum Pharmaceuticals Inc.||0||0||2||3.00|
Competitively Spectrum Pharmaceuticals Inc. has an average target price of $24, with potential upside of 116.80%.
Insider & Institutional Ownership
The shares of both Intec Pharma Ltd. and Spectrum Pharmaceuticals Inc. are owned by institutional investors at 40.62% and 84% respectively. 11.4% are Intec Pharma Ltd.â€™s share owned by insiders. Comparatively, insiders own roughly 0.6% of Spectrum Pharmaceuticals Inc.â€™s shares.
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Intec Pharma Ltd.||10.98%||30.61%||110.41%||72.58%||44.91%||49.13%|
|Spectrum Pharmaceuticals Inc.||-12.03%||-3.93%||-38.1%||-36.05%||-33.05%||-32.88%|
For the past year Intec Pharma Ltd. has 49.13% stronger performance while Spectrum Pharmaceuticals Inc. has -32.88% weaker performance.
Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The companyÃ‚â€™s lead product candidate is Accordion Pill Carbidopa/Levodopa (AP-CDLD), which is in a Phase III clinical trial for the treatment of ParkinsonÃ‚â€™s disease symptoms in advanced ParkinsonÃ‚â€™s disease patients. It is also developing Accordion Pill Zaleplon (AP-ZP) that is in a Phase III clinical trial for the treatment of insomnia, including sleep induction and for enhancing of sleep maintenance; Accordion Pill, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and Accordion Pill platform with Cannabidiol and 9-Tetrahydrocannabinol, (AP-CBD/THC), which is in a Phase I clinical trial for the treatment of various indications, including low back neuropathic pain and fibromyalgia. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd. in March 2004. Intec Pharma Ltd. was founded in 2000 and is based in Jerusalem, Israel.
Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company markets six drug products, including FUSILEV for patients with metastatic colorectal cancer and rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor to treat patients with relapsed or refractory PTCL; ZEVALIN injection for patients with follicular non-HodgkinÃ‚â€™s lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It is also developing ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer; and POZIOTINIB for treating breast and lung cancer. The company sells its drugs through a direct sales force in the United States; and through distributors in Europe. Spectrum Pharmaceuticals, Inc. has licensing and development agreement with Cell Therapeutics, Inc.; license agreement with Merck & Cie AG, Sloan-Kettering Institute, and Cydex Pharmaceuticals, Inc.; development and commercialization collaboration agreement with Allergan, Inc.; collaboration agreement with Nippon Kayaku Co., LTD.; licensing and collaboration agreement with Onxeo DK; and co-development and commercialization agreement with Hanmi Pharmaceutical Company. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.